Ambrx uses Protein Medicinal Chemistry™ to modify proteins or antibodies to create potentially best-in-class protein therapeutics.
Belrose Pharma focuses on rare diseases and uses its proprietary “releasable linker” conjugation technology and other techniques to improve the clinical efficacy of both novel therapeutics and ...
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technologies. Their integrated platform enables the discovery, design and development of ...
Working to develop the first orally administered integrin therapeutics for patients with immunological, fibrotic, neoplastic, and vascular diseases.
NeuClone works on upstream development of biosimilars including mammalian cell line development and the analytics required to confirm biosimilarity.
Small Molecules, vision and ocular related diseases, and Huntington's disease treatments
Protein Genomics carries out research and development on sophisticated, high performance biopolymers for potential applications in the wound healing, tissue regeneration, dermal filler and ...
The company works on technologies to treat lupus and Sjögren’s disease byremoving inflammatory molecules. Develops Fc - nuclease fusion proteins.
ZymoGenetics is focused on the discovery and early manufacture of therapeutic proteins.
To be closed in 2019